Literature DB >> 30128733

[Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 2 : Catatonic symptoms and neuroleptic malignant syndrome].

D Hirjak1, A Sartorius2, K M Kubera3, R C Wolf3.   

Abstract

In rare cases, pharmacotherapy in schizophrenic psychoses can be associated with life-threatening antipsychotic-induced movement disorders. The two most severe complications are antipsychotic-associated catatonic symptoms (ACS) and neuroleptic malignant syndrome (NMS). Although both constellations necessitate rapid medical care, the diagnosis is still a clinical challenge. Although there is no established treatment of ACS (here designated as a specific subtype of catatonic symptoms), an attempt should be made with benzodiazepines and memantine can also be helpful. In severe drug-refractory cases electroconvulsive therapy (ECT) can be indicated. The NMS represents a life-threatening constellation that frequently requires intensive care unit treatment. The medicinal treatment with benzodiazepines, bromocriptine, amantadine, dantrolene and/or ECT is also advocated. Finally, this review article also summarizes the currently available literature for treatment of genuine catatonic symptoms. In conclusion, the abovementioned clinical syndromes must be rapidly recognized and treated. Early recognition and treatment of these movement disorders can under certain circumstances be lifesaving and favorably influence the later clinical outcome.

Entities:  

Keywords:  Antipsychotic-associated catatonia; Catatonia; Differentialdiagnosis; Neuroleptic malignant syndrome; Therapy

Mesh:

Substances:

Year:  2019        PMID: 30128733     DOI: 10.1007/s00115-018-0581-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  3 in total

Review 1.  [The sensorimotor domain in the research domain criteria system: progress and perspectives].

Authors:  Dusan Hirjak; Stefan Fritze; Georg Northoff; Katharina M Kubera; Robert Christian Wolf
Journal:  Nervenarzt       Date:  2021-06-11       Impact factor: 1.214

2.  [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].

Authors:  D Hirjak; K M Kubera; S Bienentreu; P A Thomann; R C Wolf
Journal:  Nervenarzt       Date:  2019-05       Impact factor: 1.214

3.  Measuring catatonia motor behavior with objective instrumentation.

Authors:  Sofie von Känel; Niluja Nadesalingam; Danai Alexaki; Daniel Baumann Gama; Alexandra Kyrou; Stéphanie Lefebvre; Sebastian Walther
Journal:  Front Psychiatry       Date:  2022-08-17       Impact factor: 5.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.